Diabetes: Is rhabdomyolysis associated with DPP-IV inhibitors?
October 15, 2017 – According to the quarterly safety report April – June 2017 by the American Food & Drug Administration (FDA), originating from the FDA Adverse Event Reporting System (FAERS), the class of diabetes drugs referred to as dipeptidyl peptidase-4 …
Diabetes: Is rhabdomyolysis associated with DPP-IV inhibitors? Read more »